Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
PI3K plays a key role in cellular metabolism and cancer. Using a mass spectrometry-based metabolomics platform, we discovered that plasma concentrations of 26 metabolites, including amino acids, acylcarnitines, and phosphatidylcholines, were decreased in mice bearing PTEN-deficient tumors compared w...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , , , |
|---|---|
| Autres auteurs: | |
| Langue: | anglais |
| Publié: |
American Association for Cancer Research
2019
|
| Accès en ligne: | https://demo7.dspace.org/handle/123456789/449 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires: Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
- The Handbook of Metabonomics and Metabolomics
- Modeling in Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics : Homogeneous and Heterogeneous Approaches
- <The> effect of group interaction processes on performance in time series extrapolation.
- Pharmacokinetic/Pharmacodynamic Data Analysis: Concepts and Applications /
- Possibilities of p-glycoprotein inhibition in leukemic cells
- Vplyv vonkajšieho prostredia na metabolóm Trichoderma atroviride